Core Insights - Baiaosaitu successfully listed on the STAR Market on December 10, with a closing price increase of 146.63% to 65.80 yuan, compared to the issuance price of 26.68 yuan, marking a significant step in its capital market strategy [1] - The company has established a dual-platform listing structure with its previous listing on the Hong Kong Stock Exchange on September 1, 2022, enhancing its corporate value [1] Company Overview - Baiaosaitu is an international biotechnology company focused on innovative technology-driven drug development, addressing key industry pain points in obtaining high-quality source antibody molecules and achieving high conversion in vivo validation [2] - The company has developed a leading "dual-engine platform" system, which includes the RenMice fully human antibody platform, providing a resource library of over 1,000 potential druggable targets and more than one million real human antibody sequences [2] - Baiaosaitu also offers high-precision in vivo validation models and services for various innovative therapies, including bispecific antibodies, ADCs, and nucleic acid drugs, leveraging its extensive humanized mouse library [2] Strategic Goals - The successful A-share listing marks a new starting point for Baiaosaitu in technology platform transformation, global market expansion, and capital strategy synergy [3] - The company aims to deepen diversified cooperation with global pharmaceutical companies, reinforcing its commitment to becoming a global source of new drugs and strengthening its technological barriers [3] - As of June 30, 2025, Baiaosaitu has signed approximately 280 drug cooperation development, licensing, and transfer agreements, and has established a leading global humanized mouse library [3] - The company has a global R&D and operational network with headquarters in Beijing and branches in Jiangsu, Shanghai, Boston, San Francisco, San Diego, and Heidelberg [3]
登陆科创板首日大涨146.63%，百奥赛图构建H+A双平台格局